Please login to the form below

Not currently logged in
Email:
Password:

Summit appoints Pfizer/Bayer veteran as CMO

David Roblin to lead development of therapies for Duchenne muscular dystrophy and C.difficile

Summit David RoblinIndustry veteran Dr David Roblin has joined the Oxford, UK-based drug development and discovery company Summit as its chief medical officer.

Dr Roblin has years of senior research experience at major pharma firms, including serving as head of research, site director and chief medical officer for Europe R&D during a spell with Pfizer.

He was also head of ant-infectives at Bayer, where he led the development of several antiobiotics, including Avelox (moxifloxacin) and Cipro (ciprofloxacin).

This experience in anti-infectives will prove useful at Summit, with the company's research efforts including the development of treatments for C difficile infection in addition to potential thereapies for Duchenne muscular dystrophy.

"David brings considerable expertise in all aspects of drug development having been instrumental in the successful development of a number of important medicines,” said Summit's CEO Glyn Edwards.

“As our Duchenne muscular dystrophy and C difficile infection drug programmes go through patient clinical trials, David will make a major contribution to their successful development."

13th June 2013

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics